Korean J Neurogastroenterol Motil.  2004 Jun;10(1):27-34.

Effects of Mosapride on Upper Gastrointestinal Symptoms and Gastric Emptying in Patients with Functional Dyspepsia

• Ji SW
• Park H
• Lee PR
• Lee OY
• Kim DK

Abstract

BACKGROUND/AIMS
Mosapride is a new, prokinetic, 5-HT4 agonistic agent free of dopamine D2 receptor antagonist properties. The aim of this study was to evaluate the effects of mosapride on upper GI symptoms and gastric emptying in patients with functional dyspepsia.
METHODS
Eighty-one patients were randomly allocated to treatment with mosapride (5 mg t.i.d) (n=42) or domperidone (10 mg t.i.d) (n=39) in a single-blind, prospective, multicenter study. The changes in gastric emptying and symptom severity score after 2-week treatment were evaluated for the treatment efficacy.
RESULTS
The proportion of patients with symptom improvement more than 50% after medications was 84.6% in the mosapride-treated group and 80.6% in the domperidone-treated group, and this difference was not significant (p=0.6426). In both groups, gastric emptying measured at 120 minutes after test meal was significantly accelerated after 2-week treatment compared with that of baseline. However, there was no significant difference between the two groups after 2-week treatment. Mosapride was well tolerated, and no serious adverse events were observed.
CONCLUSIONS
Mosapride is a safe and useful drug for the treatment of patients with functional dyspepsia.

Keyword

Functional dyspepsia; Mosapride

MeSH Terms

Domperidone
Dyspepsia*
Gastric Emptying*
Humans
Meals
Prospective Studies
Receptors, Dopamine D2
Serotonin 5-HT4 Receptor Agonists
Treatment Outcome
Domperidone
Receptors, Dopamine D2
Serotonin 5-HT4 Receptor Agonists